Indaptus Therapeutics is trading 26.39% up at $1.19, with no clear company-specific catalyst identified for August 20, 2026.
- Latest notable disclosures were second-quarter results released August 13 and an August 17 prospectus registering resale of up to 58.895 million existing shares; neither directly explains today’s advance.
- Broader equities and biotechnology are moving lower, so the gain is not clearly attributable to sector or market direction.
- The move may reflect trading activity or speculative demand, but confirmation is unavailable.